Elinzanetant Effectively Reduces Vasomotor Symptoms in Breast Cancer Patients on Endocrine Therapy
A new phase 3 trial shows that elinzanetant significantly reduces hot flashes and night sweats in women undergoing endocrine therapy for breast cancer, improving quality of life.
A recent phase 3 clinical trial has demonstrated that elinzanetant, a neurokinin receptor-targeted medication, significantly decreases vasomotor symptoms such as hot flashes and night sweats in women undergoing endocrine therapy for hormone receptor-positive breast cancer. Published online on June 2, 2025, in the New England Journal of Medicine, the study was presented during the American Society of Clinical Oncology annual meeting held from May 31 to June 4 in Chicago.
The research was led by Dr. Fatima Cardoso from the Champalimaud Foundation in Lisbon, Portugal. It involved women aged 18 to 70 experiencing moderate-to-severe vasomotor symptoms linked to endocrine therapy either for breast cancer treatment or prevention. Participants were randomly assigned to receive daily doses of 120 mg of elinzanetant for 52 weeks or a placebo for the initial 12 weeks, followed by elinzanetant for 40 weeks. A total of 474 women participated, with only one using endocrine therapy for breast cancer prevention.
Results showed that women treated with elinzanetant had a greater reduction in vasomotor symptom frequency. At week 4, the average decline was 6.5 episodes per day compared to 3.0 episodes in the placebo group. By week 12, the reductions were 7.8 and 4.2 episodes, respectively. The study also noted that about 70% of women on elinzanetant experienced at least one adverse event, with serious adverse events occurring in 2.5% versus 0.6% in the placebo group. Despite this, the drug's benefits in alleviating symptoms and improving quality of life were deemed significant.
The authors highlighted that these findings are consistent with previous research in postmenopausal women, suggesting elinzanetant as a promising therapy for managing vasomotor symptoms. Certain authors disclosed financial ties to Bayer, the pharmaceutical company developing elinzanetant, which funded the study.
This innovative treatment offers hope for women suffering from menopause-like symptoms caused by cancer treatments, providing a new pathway to improve comfort and overall health during breast cancer management.
Source: https://medicalxpress.com/news/2025-06-elinzanetant-vasomotor-symptoms-women-breast.html
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
New Research Links Tea and Dark Chocolate Consumption to Lower Blood Pressure
New research reveals that daily consumption of tea, dark chocolate, and flavan-3-ol-rich foods may help lower blood pressure and improve vascular health, offering a natural approach to cardiovascular wellness.
Combination Therapy Shows Promise and Safety for Specific Genetic Types of Acute Myeloid Leukemia
New clinical research indicates that combining standard AML treatment with targeted drugs like revumenib offers high remission rates and safety for patients with specific genetic mutations, paving the way for personalized therapy approaches.
Barriers to Adopting Healthy Lifestyles Among Teens Revealed in Recent Study
A recent study uncovers the structural barriers such as poverty, discrimination, and mental health issues that hinder teenagers' access to healthy diets and physical activity, emphasizing the need for systemic reforms to promote youth well-being.
Cellular Signature Unveiled as Key to Prostate Tumor Treatment Resistance
A groundbreaking study uncovers a cellular signature linked to prostate tumor resistance, paving the way for personalized treatments and earlier chemotherapy interventions.